

## ADUHELM (aducanumab-avwa) Infusion Orders

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_  Male  Female

Diagnosis (please provide ICD10 code) : \_\_\_\_\_

NKDA Allergies: \_\_\_\_\_ Patient Weight (lbs/kg): \_\_\_\_\_

New Start Therapy  Continuation of Therapy Date of last dose (if applicable): \_\_\_\_\_

### Ordering Provider:

Provider NPI: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Practice Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_

#### PRE-MEDICATION

- Acetaminophen 1000mg PO  Solu-Medrol 125mg IVP  
 Diphenhydramine 25mg PO  Solu-Cortef 100mg IVP  
 Ceterizine 10mg PO  Diphenhydramine 25mg IVP

#### ADUHELM ORDERS

- IV Infusion every 4 weeks, administered over approximately one hour  
- Dilute in 100 mL of 0.9% Sodium Chloride (remove equal volume from bag)  
- Use 0.2 micron in-line filter
- ADUHELM Dosage:  
- Infusion 1 and 2: **1 mg/kg**  
- Infusion 3 and 4: **3 mg/kg**  
- Infusion 5 and 6: **6 mg/kg**  
- Infusion 7 and beyond: **10 mg/kg**

#### Sage Infusion Standing Orders:

- Provide treatment under Sage Infusion's Clinical Guidelines, Medication Safety Protocol, Emergency Guidelines, and Action Plan for Infusion Reactions

\_\_\_\_\_  
Provider Name

\_\_\_\_\_  
Provider Signature

\_\_\_\_\_  
Date

#### REQUIRED IMAGING

- Amyloid Beta confirmation documentation (required for insurance authorization)
- Recent (within one year) brain MRI prior to initiating treatment. Date of MRI \_\_\_\_\_ (please provide a copy of imaging)
- Brain MRI prior to the **5th** infusion (first dose of 6 mg/kg) Date of MRI \_\_\_\_\_ (Please provide copy of imaging)
- Brain MRI prior to the **7th** infusion (first dose of 10 mg/kg) Date of MRI \_\_\_\_\_ (Please provide copy of imaging)
- Brain MRI prior to the **9th** infusion (third dose of 10 mg/kg) Date of MRI \_\_\_\_\_ (Please provide copy of imaging)
- MRI prior to the **12th** infusion (sixth dose of 10 mg/kg). Date of MRI \_\_\_\_\_ (Please provide copy of imaging)

*\*Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 8 doses of treatment with ADUHELM, particularly during titration. If a patient experiences symptoms which could be suggestive of ARIA, clinical evaluation should be performed, including MRI testing if indicated.*

Obtain MRIs prior to the 7th and 12th infusions. If radiographic severe ARIA-H is observed, treatment may be continued with caution only after a clinical evaluation and a follow-up MRI demonstrates radiographic stabilization (i.e., no increase in size or number of ARIA-H).

Most common adverse reactions (at least 10% and higher incidence compared to placebo): ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, and fall.